
PreDicta
Pre/Dicta offers both court-facing strategic litigation intelligence and client-facing business advisory intelligence,
Court-Facing Strategic Litigation Intelligence
Motion Strategy:
Fine-tune your motion to dismiss strategy, revealing just enough to achieve the desired outcome while preserving broader litigation tactics.
Settlement & Negotiation Strategy:
Pinpoint optimal moments to push, settle, or time negotiations by predicting when your party’s leverage or procedural advantages are strongest.
Defendant and Venue Strategy:
Strategically add or exclude defendants to influence venue selection and optimize your chances of dismissal before discovery.
Litigation Timelines:
Predict with accuracy how long it will take for rulings, allowing you to align litigation budgets and resources efficiently.
Client-Facing Business Advisory Intelligence
Business-Aligned Litigation Strategy:
Align litigation strategies with clients’ business goals, providing legal advice that is both precise and strategic.
Executive-Level Guidance:
Offer predictive insights to C-suites and boards around litigation’s potential impact on business performance, shareholder returns, and operations.
Risk & Impact Advisory:
Translate litigation risks into business terms, helping clients assess and manage regulatory, operational, or reputational exposure.
Outcome and Risk Forecasting:
Help clients anticipate potential outcomes and plan for multiple litigation scenarios, ensuring business continuity in any situation.
In January 2023, Pre/Dicta acquired state court data from Gavelytics.
PreDicta Expands Litigation Analytics Platform to California, Its First Venture Into State Courts

Pre/Dicta Acquires Shuttered Gavelytics in Push to Accelerate State Court Predictions
New Judicial Analytics Product Predicts Motion Outcomes with Claimed 86.7% Accuracy
Loading...